HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme 		Help

New: Introducing the Finviz Crypto Map

Learn More

URGN

UroGen Pharma Ltd

Last Close
Jul 16 • 12:02PM ET
14.24
Dollar change
+0.20
Percentage change
1.46 		%
Healthcare • Biotechnology • USA • NASD
Peers: SRPT BIIB EXEL IONS FOLD ACAD NBIX VKTX PBYI HALO
 | Held by: IWM IWO IBB VTWO IZRL SPDW IWC IWN VTWG SBIO
Scroll to Statements
IndexRUT P/E- EPS (ttm)-3.18 Insider Own14.08% Shs Outstand46.10M Perf Week3.15%
Market Cap656.80M Forward P/E- EPS next Y-1.08 Insider Trans-0.26% Shs Float39.62M Perf Month18.41%
Enterprise Value586.19M PEG- EPS next Q-0.83 Inst Own96.76% Short Float13.76% Perf Quarter34.39%
Income-138.43M P/S7.15 EPS this Y1.54% Inst Trans28.51% Short Ratio1.81 Perf Half Y39.93%
Sales91.87M P/B- EPS next Y62.95% ROA-61.77% Short Interest5.45M Perf YTD33.76%
Book/sh-1.01 P/C3.33 EPS next 5Y- ROE- 52W High18.15 -21.52% Perf Year-15.86%
Cash/sh4.27 P/FCF- EPS past 3/5Y15.81% 10.39% ROIC-176.37% 52W Low3.42 316.52% Perf 3Y67.19%
Dividend Est.- EV/EBITDA- Sales past 3/5Y23.46% 449.77% Gross Margin89.68% Volatility6.60% 8.42% Perf 5Y-39.77%
Dividend TTM- EV/Sales6.38 EPS Y/Y TTM6.32% Oper. Margin-117.51% ATR (14)1.01 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.47 Sales Y/Y TTM8.98% Profit Margin-150.68% RSI (14)62.60 Recom1.25
Dividend Gr. 3/5Y- - Current Ratio5.65 EPS Q/Q4.41% SMA202.82% Beta1.11 Target Price34.38
Payout- Debt/Eq- Sales Q/Q7.84% SMA5040.36% Rel Volume0.19 Prev Close14.04
Employees235 LT Debt/Eq- EarningsMay 12 BMO SMA20030.00% Avg Volume3.02M Price14.24
IPOMay 04, 2017 Option/ShortYes / Yes EPS/Sales Surpr.-15.10% -11.14% Trades Volume239,289 Change1.46%
Date Action Analyst Rating Change Price Target Change
Jun-16-25Upgrade H.C. Wainwright Neutral → Buy $50
May-22-25Downgrade H.C. Wainwright Buy → Neutral
Apr-16-25Initiated Scotiabank Sector Outperform $23
Feb-19-25Resumed Ladenburg Thalmann Buy $31
Aug-22-24Initiated Guggenheim Buy $40
Feb-08-23Downgrade Jefferies Buy → Hold $35 → $10
Apr-27-22Initiated Berenberg Buy $20
Apr-16-20Reiterated H.C. Wainwright Buy $53 → $57
Apr-13-20Reiterated H.C. Wainwright Buy $75 → $53
Jan-09-20Initiated National Securities Neutral $37
Show Previous Ratings
Jul-08-25 11:48AM
UroGen concludes enrolment in Phase III trial of UGN-103 for bladder cancer
(Clinical Trials Arena)
Jul-07-25 08:00AM
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
(GlobeNewswire)
Jul-06-25 04:01AM
UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer
(Insider Monkey)
Jun-17-25 01:32PM
H.C. Wainwright Sees Billion Dollar Potential in UroGen's New Therapy
(Insider Monkey) -7.67%
Jun-13-25 12:40PM
FDA approves UroGens Zusduri for non-muscle invasive bladder cancer
(TipRanks) +8.57%
06:00AM Loading…
06:00AM
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans
(BioPharma Dive)
05:45AM
UroGen Pharma Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 28, 2025 to Discuss Your Rights - URGN
(PR Newswire)
Jun-12-25 01:28PM
U.S. FDA Approves UroGens ZUSDURI (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
(Business Wire) +51.78%
Jun-06-25 08:00AM
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire) +43.39%
Jun-02-25 11:00AM
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer
(Business Wire) +14.15%
10:00AM
UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
(Business Wire)
May-29-25 01:45PM
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman
(PR Newswire)
May-27-25 04:00PM
UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA
(Business Wire) -6.21%
May-22-25 06:52AM
FDA advisers pan Pfizers PARP drug; Sarepta to resume Duchenne study
(BioPharma Dive)
May-21-25 12:17PM
UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
(Business Wire) -44.69%
10:55AM Loading…
May-20-25 10:55AM
Biotech Alert: Searches spiking for these stocks today
(TipRanks) -5.40%
May-13-25 03:05AM
UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ...
(GuruFocus.com) -8.98%
May-12-25 09:15AM
Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates
(Zacks) +7.32%
08:00AM
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
(Business Wire)
May-07-25 10:32AM
Pfizer, J&J, Genentech drugs subject of FDA advisory panel meeting this month
(Seeking Alpha)
10:22AM
UroGen's bladder cancer treatment to be reviewed by FDA advisory committee
(Seeking Alpha)
08:57AM
UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
(Business Wire)
May-01-25 04:00PM
UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
(Business Wire)
Apr-29-25 05:16AM
Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?
(Zacks)
Apr-27-25 04:00PM
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment
(Business Wire)
01:00PM
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
(Business Wire)
12:30PM
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
(Business Wire)
Apr-26-25 06:30PM
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
(Business Wire)
10:00AM
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer
(Business Wire)
Apr-14-25 08:00AM
UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers
(Business Wire)
10:02AM Loading…
Apr-12-25 10:02AM
UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy
(Seeking Alpha)
Mar-12-25 03:00PM
UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ...
(GuruFocus.com)
Mar-10-25 09:10AM
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
(Zacks)
08:00AM
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
(Business Wire)
Mar-07-25 08:00AM
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Feb-27-25 08:00AM
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
(Business Wire)
Feb-25-25 12:30PM
Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?
(Insider Monkey)
Feb-24-25 04:00PM
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
(Business Wire)
Feb-21-25 10:53AM
UroGen acquires IconOVirs oncolytic virus assets
(Pharmaceutical Technology) -5.88%
Feb-20-25 08:00AM
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
(Business Wire)
Feb-14-25 02:30PM
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
(Business Wire)
Feb-12-25 08:00AM
Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology
(Business Wire)
Jan-30-25 08:00AM
UroGen Pharma to Present at Upcoming Investor Conferences
(Business Wire)
Jan-22-25 08:00AM
New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
(Business Wire)
Jan-15-25 08:00AM
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025
(Business Wire)
Dec-06-24 08:00AM
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Dec-05-24 03:30PM
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO
(Business Wire)
03:15PM
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
(Business Wire)
Dec-02-24 05:44PM
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade
(Zacks)
08:00AM
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
(Business Wire)
Nov-28-24 11:49AM
UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment
(Clinical Trials Arena)
Nov-26-24 08:00AM
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO
(Business Wire)
Nov-07-24 02:16AM
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
(GuruFocus.com)
Nov-06-24 09:15AM
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates
(Zacks)
08:00AM
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
(Business Wire)
Nov-05-24 08:00AM
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
(Business Wire)
Oct-30-24 08:00AM
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
(Business Wire) +6.29%
Oct-28-24 08:00AM
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
(Business Wire)
Oct-16-24 04:47AM
FDA accepts UroGens UGN-102 NDA for bladder cancer treatment
(Pharmaceutical Technology)
Oct-15-24 04:30PM
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
(Business Wire)
Oct-09-24 06:18PM
UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
(GuruFocus.com) -9.31%
08:00AM
UroGen Appoints Chris Degnan as Chief Financial Officer
(Business Wire)
Oct-03-24 04:12AM
UroGen begins subject dosing in Phase III bladder cancer drug trial
(Clinical Trials Arena)
Oct-02-24 08:00AM
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
(Business Wire)
Sep-23-24 05:50AM
UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now
(Insider Monkey)
03:58AM
UroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR Stock
(Insider Monkey)
Sep-16-24 08:00AM
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
(Business Wire)
Sep-05-24 08:00AM
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Aug-29-24 08:00AM
UroGen Pharma to Present at Upcoming Investor Conferences
(Business Wire)
Aug-14-24 08:00AM
UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
(Business Wire)
Aug-13-24 09:15AM
Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
08:00AM
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
(Business Wire)
Aug-05-24 08:00AM
UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
(Business Wire)
Aug-02-24 09:55AM
Does Urogen Pharma (URGN) Have the Potential to Rally 171.05% as Wall Street Analysts Expect?
(Zacks)
Aug-01-24 10:01AM
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
(Zacks)
Jul-17-24 09:55AM
Wall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High?
(Zacks)
Jun-27-24 01:54PM
UroGen Pharma Stock Earns 91 RS Rating
(Investor's Business Daily)
Jun-17-24 10:51PM
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
(Business Wire) -7.71%
04:46PM
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
(GlobeNewswire)
05:00AM
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
(Zacks)
Jun-13-24 04:05PM
UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug
(Investor's Business Daily) +37.58% +9.71%
10:45AM
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
(Business Wire)
Jun-07-24 08:00AM
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Jun-06-24 08:00AM
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
(Business Wire)
Jun-05-24 08:00AM
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
(Business Wire)
Jun-03-24 08:00AM
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
(Business Wire)
May-22-24 08:00AM
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
(Business Wire)
May-14-24 08:20AM
UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2024 Earnings Call Transcript
(Insider Monkey)
May-13-24 12:53PM
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024
(InvestorPlace)
09:32AM
UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations
(GuruFocus.com)
08:00AM
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
(Business Wire)
May-07-24 08:00AM
UroGen Pharma to Participate at Upcoming Investor Conferences
(Business Wire)
May-05-24 12:20PM
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
(Business Wire)
May-04-24 03:20PM
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
(Business Wire)
11:50AM
New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
(Business Wire)
May-03-24 08:00AM
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
(Business Wire)
Apr-17-24 12:02PM
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
(Business Wire)
Apr-15-24 08:00AM
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
(Business Wire)
Apr-03-24 08:00AM
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
(Business Wire)
Mar-15-24 10:30AM
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript
(Insider Monkey)
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schoenberg MarkChief Medical OfficerJun 09 '25Sale7.375,16238,044153,378Jun 11 09:14 AM
Schoenberg MarkOfficerJun 09 '25Proposed Sale7.375,16238,044Jun 10 09:27 AM
Schoenberg MarkChief Medical OfficerJan 31 '25Sale11.144,55150,698145,666Feb 04 11:53 AM
Smith Jason DrewGeneral CounselJan 31 '25Sale11.147,37982,20226,468Feb 04 11:51 AM
Schoenberg MarkChief Medical OfficerSep 09 '24Sale13.0885911,236145,091Sep 12 01:54 PM
Smith Jason DrewGeneral CounselSep 09 '24Sale13.081,52119,89525,226Sep 12 01:51 PM
Schoenberg MarkOfficerSep 09 '24Proposed Sale13.2385911,365Sep 10 07:16 AM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Theme Settings • Contact • Blog • Help • Privacy • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.